- Home
- GIGM vs PPBT Comparison
GIGM vs PPBT Comparison
Compare GIGM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | PPBT |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | Taiwan | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 45.3M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GIGM | PPBT |
|---|---|---|
| Price | $1.47 | $3.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 4.3K | ★ 11.8K |
| Earning Date | 05-04-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.37 | $0.41 |
| 52 Week High | $1.89 | $5.18 |
Technical Indicators
Market Signals| Indicator | GIGM | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 63.89 |
| Support Level | $1.42 | $0.57 |
| Resistance Level | $1.60 | $5.18 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 33.33 | 68.57 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.